SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

A leak of Phase 3 melanoma-vaccine results drove a sharp selloff, even though the combination with Keytruda reduced recurrence-or-death risk; traders focused on whether the benefit fell short of lofty expectations after the stocks steep run-up. The community is split between viewing the drop as an overreaction and arguing that valuation and the data justify further repricing, with volatile rebounds adding to the debate.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy shares are selling off despite a strong quarterly earnings beat and raised full-year guidance, with traders pointing to negative cash flow and heavy investment in capacity as concerns. The debate centers on whether the drop reflects cash-generation and valuation risks or broader selling of AI-related stocks despite continued data-center power demand.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff, amid concerns about AI spending and financing, weakness in major chip stocks, and geopolitical tensions pushing oil higher, has hammered SOXL; its daily 3x leverage magnifies the move. Traders are divided between calling the drop an oversold buying opportunity and warning that the AI trade could weaken further.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals strong quarterly results and upbeat outlook have been overshadowed by a sharp selloff alongside AI, memory, and storage stocks. Traders debate whether the decline reflects broader risk-off sentiment and concerns about cyclical peak earnings, rising costs, and future supply, or an overreaction given robust data-center demand.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokias Q3 results beat expectations, but shares fell sharply as traders focused on weaker free-cash-flow conversion guidance, higher restructuring costs and managements warning of structural supply-chain cost increases. The community is split between investors calling the selloff an overreaction given strong AI and cloud growth and bears concerned about cash generation and the cautious outlook.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a sharp semiconductor selloff, with traders debating whether concerns about AI infrastructure spending, debt financing and returns signal a deeper unwind; higher oil prices and interest-rate worries are adding to risk aversion. Some see oversold conditions and support as a buying opportunity, while others expect further losses and view the AI trade as vulnerable.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is being discussed alongside weakness in AI infrastructure and neocloud stocks, amid concerns about debt-funded data-center expansion and broader market risk-off pressure. Traders are split between viewing the decline as an oversold buying opportunity tied to IRENs AI buildout and seeing further downside risk; some also point to short selling, though that explanation is speculative.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A sharp semiconductor selloff is driving attention, as traders weigh concerns about AI spending and financing against weakness in the broader Nasdaq and geopolitical-driven oil worries. The community is split between dip buyers watching for a technical rebound and bears warning that the AI trade could unwind further.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp Nasdaq-led tech selloff, with traders focused on doubts that heavy AI and data-center spending will generate adequate returns and steep losses in semiconductor stocks; higher oil prices amid U.S.-Iran tensions added to market pressure. The conversation is broadly bearish, though some traders view the decline as a buying opportunity and are watching for a bounce around support.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers quarterly report sparked a sharp selloff despite an earnings beat: traders focused on a revenue miss and reduced full-year sales outlook, while higher EPS guidance was partly supported by tariff refunds. The community is split between viewing the drop as an overreaction given strong margins and buybacks, and worrying that HOKA and UGG growth is slowing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes OKYO Pharma (OKYO) a New Buy Stock

OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of "Hold" from Analysts

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) has earned an average recommendation of 'Hold' from the five analysts that are presently covering the firm, MarketBeat.com reports...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 272,194 shares, an increase of 31.9% from the March 31st total of 206,345 shares. Based on...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 25.0% in March

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have been given an average rating of "Hold" by the five analysts that are covering the firm, Marketbeat.com reports. One...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant drop in short interest in February. As of February 27th, there was short interest totaling 435,430...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of "Hold" from Analysts

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are covering the firm, Marketbeat.com reports. One...

OKYO Pharma (NASDAQ:OKYO) Raised to "Strong-Buy" at Piper Sandler

Piper Sandler raised OKYO Pharma to a "strong-buy" rating in a report on Friday...

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have earned a consensus rating of "Hold" from the five ratings firms that are presently covering the firm, MarketBeat.com...

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited - Ordinary Shares - New

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug

Equity

Bullish Sentiment

Shares of OKYO Pharma (OKYO) jumped 8% on Monday morning after the company said that it is now planning to advance to a multiple-ascending-dose (MAD) clinical trial for its lead drug candidate Urcosimod.Urcosimod is being developed to treat neuropathic corneal pain (NCP), a condition that causes severe pain and sensitivity of the eyes, face, or head, and is thought to result from nerve damage to the cornea combined with inflammation.In July, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://okyopharma.com/okyo-pharma-announces-registration-pathway-with-100-patient-multi-center-clinical-trial-of-urcosimod-in-neuropathic-corneal-pain/">announced</a> data from a mid-stage trial of Urcosimod in 17 NCP patients. After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% Urcosimod showed greater than 80% reduction in neuropathic corneal pain in that study, as measured by visual analog scale.Okyo said on Monday that it is now focused on advancing to a multiple-ascending-dose (MAD) clinical trial designed to enroll approximately 100 NCP patients across several U.S. clinical sites. The purpose of the trial is to identify the optimal registration dose for Urcosimod for future late-stage trials and to develop an understanding of the drug’s characteristics.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OKYO">OKYO stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_1_09_35_PM_png_4bfce5981c.webp" alt="OKYO's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="578" height="57"><figcaption>OKYO's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that they now see a “clear route forward.”<stembedurl>https://stocktwits.com/rp6577/message/629485633</stembedurl>The company said that it expects data from this new trial in 2026, and negotiations are underway with several clinical sites in the U.S. Okyo continues to progress toward a meeting with the U.S. Food and Drug Administration (FDA) to discuss requirements for an approvable drug to treat NCP and to define the primary endpoint required for potential registration, it said.“Our next &nbsp;MAD clinical trial is designed to give us the data needed to define an optimal registration pathway for urcosimod, and we are moving rapidly to initiate this study. With Fast-Track designation in place and a constructive engagement anticipated with FDA, we are well-positioned to bring this novel therapy closer to patients in need,” said CEO Gary S Jacob.OKYO stock is up 85% this year and approximately 112% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-awarded-with-yet-another-price-target-hike-after-waymo-partnership/chDQu3aR32s">Lyft Awarded With Yet Another Price Target Hike After Waymo Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Okyo announced on Monday that it is now focused on advancing to a multiple-ascending-dose clinical trial, designed to enroll approximately 100 patients with neuropathic corneal pain across several U.S. clinical sites.

Pharma Limited

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Current Price	$1.47
Prev Close	$1.54
Open	$1.50
Dividend Yield	0.00%
50-Day Moving Average	$1.45
Beta	0.82
Avg. Volume	84,359.80
PE Ratio	-7.72

52-Week High	$3.20
52-Week Low	$1.26
Market Capitalization	$80.82M
EPS (Annual)	-$0.2396
Price to Book	6.25
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

OKYO Fundamentals